Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Kalaris Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 75 | 84 | +9 |
| Shares | 26.7M | 26.4M | −267.1K (−1.0%) |
| Value | $624.4M | $521.8M | −$102.6M (−16.4%) |
New holders (20)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Lido Advisors, LLC | 419,631 | $8.28M | 0.20% |
| Millennium Management LLC | 87,195 | $1.72M | 0.00% |
| HRT Financial LP | 80,181 | $1.58M | 0.01% |
| Twin Focus Capital Partners, LLC | 59,359 | $1.17M | 0.27% |
| Tudor Investment Corp Et Al | 35,480 | $700.0K | 0.01% |
| Voloridge Investment Management, LLC | 28,504 | $563.0K | 0.00% |
| Renaissance Technologies LLC | 28,000 | $553.0K | 0.00% |
| Squarepoint Ops LLC | 21,848 | $431.0K | 0.00% |
| Jane Street Group, LLC | 18,986 | $375.0K | 0.00% |
| Invesco Ltd. | 14,491 | $286.0K | 0.00% |
| ExodusPoint Capital Management, LP | 14,000 | $276.0K | 0.00% |
| Handelsbanken Fonder AB | 13,400 | $265.0K | 0.00% |
| UBS Asset Management Americas Inc | 13,356 | $263.6K | 0.00% |
| Parametric Portfolio Associates LLC | 12,910 | $255.0K | 0.00% |
| Benjamin F. Edwards & Company, Inc. | 1,554 | $31.0K | 0.00% |
| Nisa Investment Advisors, LLC | 1,000 | $20.0K | 0.00% |
| US Bancorp | 160 | $3.00K | 0.00% |
| Advisory Services Network, LLC | 139 | $3.00K | 0.00% |
| TCI Wealth Advisors, Inc. | 87 | $2.00K | 0.00% |
| Signaturefd, LLC | 38 | $1.00K | 0.00% |
Sold out (11)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Marshall Wace, LLP | 152,939 | $3.58M |
| D. E. Shaw & Co., Inc. | 61,672 | $1.44M |
| TCW Group Inc | 40,667 | $951.0K |
| California Public Employees Retirement System | 34,700 | $812.0K |
| Walleye Capital LLC | 31,845 | $745.0K |
| Caption Management, LLC | 28,000 | $656.0K |
| Laurion Capital Management LP | 25,000 | $585.0K |
| Jump Financial, LLC | 15,002 | $351.0K |
| Trexquant Investment LP | 11,218 | $263.0K |
| Pacer Advisors, Inc. | 1,740 | $41.0K |
| Bank of Montreal | 871 | $21.0K |